Abiopharma

DelphX is a technology and financial services company focused on bringing new and exciting alternatives to structured product and credit markets. Through its special purpose vehicle Quantem and its broker-dealer DelphX Services Corp, it enables fixed income dealers to offer new Rule 144A securities that optimally transfer and diffuse credit risk, while allowing the enhancement of yield. All CPOs and CRNs are issued by Quantem, collateralized by US Treasuries and held in custody by BNY Mellon. At no time does DelphX (or Quantem) hold any securities or funds on behalf of third parties. DelphX has officially launched its products to the institutional buyside and broker-dealer community and anticipates near term adoption and monetization especially as economic and market conditions continue to demonstrate the need for risk mitigation and yield enhancement in credit portfolios.

Additional info from OTC:
DelphX is a technology and financial services company focused on bringing new and exciting alternatives to structured product and credit markets. Through its special purpose vehicle Quantem and its broker-dealer DelphX Services Corp, it enables fixed income dealers to offer new Rule 144A securities that optimally transfer and diffuse credit risk, while allowing the enhancement of yield. All CPOs and CRNs are issued by Quantem, collateralized by US Treasuries and held in custody by BNY Mellon. At no time does DelphX (or Quantem) hold any securities or funds on behalf of third parties. DelphX has officially launched its products to the institutional buyside and broker-dealer community and anticipates near term adoption and monetization especially as economic and market conditions continue to demonstrate the need for risk mitigation and yield enhancement in credit portfolios.